Patent intelligence · US
US 11278573
Methods and compositions to facilitate repair of avascular tissue
Methods and compositions to facilitate repair of avascular tissue
Patent details — US 11278573
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 22, 2022
- Expiration
- Mar 17, 2042
- Applicant
- Regenexx, LLC
- Claims
- 13
- CPC classes
- A61K, A61K35/19, A61K35/28, A61K38/18
Quick answer
US 11278573 (Methods and compositions to facilitate repair of avascular tissue) is held by Regenexx, LLC. Status: granted. Granted Mar 22, 2022. Expires Mar 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Regenexx, LLC
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K35/19, A61K35/28, A61K38/18, A61K38/19, A61P
More from Regenexx, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11278573?
US 11278573 (Methods and compositions to facilitate repair of avascular tissue) is held by Regenexx, LLC. Status: granted. Granted Mar 22, 2022. Expires Mar 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11278573?
Regenexx, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11278573 expire?
Our index shows an expiration date of Mar 17, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.